Corres. and Mail

Attorney Docket No. 9950-0002 **PATENT**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on

Group Art Unit: 1644

Examiner: P. Huynh

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPERS ORIGINALLY FILE

n Re Application of: ULRICH et al.

U.S. Serial No.: 09/402,273

U.S. Filing Date: December 13, 1999

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith for filing is an amendment in the above patent application in response to the Office Action of December 18, 2001.

__X

Also enclosed: Return Post Card.

X

No additional amendment fee is required.

No. of Claims After Amendment	r		Most Claims Previously Paid		Extra Claims				Additional Fee
A. Total Claims	5	-	20	=	0	х	\$18	=	0.00
B. Ind. Claims	1	•	4	=	0	х	\$84	=	0.00
C. If amended to contain multiple dependent claims, add \$280 \$280								=	0.00
D. Total Amendment Fee (Total of A, B & C)								=	0.00
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	0.00
F. Total Amendment Fee (D minus E)								=	0.00

The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

By:

. Elin Hartrum

Registration No. 43,663

REED & ASSOCIATES 800 Menlo Avenue, Suite 210 Menlo Park, California 94025 (650) 330-0900 Telephone (650) 330-0980 Facsimile

F:\Document\9950\0002\Amend 1.116 xtl.wpd

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

Attorney Docket No. 9950-0002 Serial No. 09/402,273

Pate: 19 7cb 7002

Signature

MAR 1 1 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: P. Huynh

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

AMENDMENT UNDER 37 CFR § 1.116 EXPEDITED PROCEDURE: GROUP ART UNIT 1644

Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the final Office Action in the above-identified case, mailed on December 18, 2001. Reconsideration of the application in view of the following remarks and amendments is respectfully requested.

AMENDMENTS

IN THE CLAIMS:

Please amend claim 1 as indicated in Appendix A. The amended claim reads as follows:

1. (Twice Amended) A pharmaceutical composition capable of selectively enhancing a TH₁ response comprising tyrosine, an allergen or allergen extract, optionally modified by reaction with a cross-linking agent, and 3-DMPL.